grant
DF/HCC Prostate SPORE
Organization DANA-FARBER CANCER INSTLocation BOSTON, UNITED STATESPosted 1 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AccelerationActive Follow-upAcuteAddressAmerican maleAmerican manAmerican menAndrogen ReceptorAssayAutopsyBackBasic ResearchBasic ScienceBioassayBiologicalBiological AssayBiological MarkersBiometricsBiometryBiostatisticsBloodBlood Reticuloendothelial SystemBlood SampleBlood specimenBody TissuesCancer BiologyCancer CauseCancer CenterCancer EtiologyCancersCaringCessation of lifeClinicalClinical InvestigatorClinical ResearchClinical SciencesClinical StudyClinical TrialsCollaborationsCommunicationCommunitiesComputational BiologyDF/HCCDana-Farber Cancer InstituteDataDeathDedicationsDevelopmentDiagnosisDiseaseDisease ResistanceDisorderDorsumENX-1EZH1EZH2EZH2 geneEarly DiagnosisEarly treatmentEnhancer of Zeste 2 Polycomb Repressive Complex 2 SubunitEnsureEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFosteringFundingGeneral HospitalsGeneralized GrowthGenomicsGoalsGrowthHospitalsIndividualInduction TherapyInfrastructureInstitutionInvestigatorsIsraelKMT6KMT6ALaboratoriesLaboratory ResearchLeadMachine LearningMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMassachusettsMedical centerMentorsMolecularMorbidityMorbidity - disease rateNEOADJNGS MethodNGS systemNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNewly DiagnosedPathologyPathway interactionsPatient advocacyPatientsPb elementPhenotypePopulation SciencesPre-Clinical ModelPreclinical ModelsPrognostic MarkerProstateProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate GlandProstate malignancyProstatic GlandReproduction sporesResearchResearch PersonnelResearch ResourcesResearch SpecimenResearchersResistanceResistance developmentResistant developmentResourcesServicesSpecimenSporesTherapeuticTissue GrowthTissuesTranslatingTranslational ResearchTranslational ScienceTranslationsU.S. MalesUS MenUS maleWorkactive followupandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate canceranti-cancer researchbench bed sidebench bedsidebench to bed sidebench to bedsidebench to clinicbench to clinical practicebio-markersbiologicbiologic markerbiomarkerbiomarker developmentbiomarker discoverybiomarker drivencancer genomicscancer initiationcancer progressioncancer researchcareercastration resistant CaPcastration resistant PCacastration resistant prostate cancerclinical translationclinically translatablecohortcombatcomputer biologycustomized therapycustomized treatmentdata sharingdeep learningdeep learning methoddeep learning strategydepositorydeveloping resistancedevelopmentaldrug standardearly detectionearly therapyepigeneticallyepigenomefollow upfollow-upfollowed upfollowupheavy metal Pbheavy metal leadhigh riskhormone refractory prostate cancerimprovedimproved outcomeindividualized cancer careindividualized medicineindividualized oncologyindividualized patient treatmentindividualized therapeutic strategyindividualized therapyindividualized treatmentinduction therapiesinnovateinnovationinnovativeinsightmachine based learningmales in Americamales in the U.S.males in the USmales in the USAmales in the United Statesmalignancymeetingmeetingsmenmen in Americamen in the U.S.men in the USmen in the USAmen in the United Statesmodel developmentmodel developmentsmortalitynecropsyneoplasm progressionneoplasm/cancerneoplastic progressionnew approachesnext gen sequencingnext generationnext generation sequencingnextgen sequencingnovelnovel approachesnovel strategiesnovel strategyoncogenomicsontogenypathwaypatient populationpatient specific therapiespatient specific treatmentpersonalized oncologypostmortempre-clinicalpre-clinical studyprecision cancer careprecision cancer medicineprecision medicineprecision oncologyprecision-based medicinepreclinicalpreclinical studyprognostic biomarkerprognostic indicatorprogramsprostate cancer resistant to androgenprostate cancer riskprostate cancer treatmentrepositoryresistance mechanismresistance to diseaseresistance to therapyresistantresistant diseaseresistant mechanismresistant to diseaseresistant to therapysuccesstailored medical treatmenttailored therapytailored treatmenttherapeutic resistancetherapy resistanttranslationtranslation researchtranslation strategytranslational approachtranslational cancer researchtranslational investigationtranslational investigatortranslational researchertranslational scientisttranslational strategytreatment resistancetumortumor progressionunique treatment
Description preview
The Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Prostate Cancer seeks to improve the understanding and treatment of prostate cancer using a highly translational approach. The application consists of three Projects, three Cores, a Developmental Research Program and a Career Enhancement Program. The SPORE infrastructure will facilitate…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click